

Executive Corridor  
Darlington Memorial Hospital  
Hollyhurst Road  
Darlington  
DL3 6HX  
Switchboard Tel: 01325 38 0100  
Foundation Trust Office: 01325 74 3625  
Corporate Records Office: 01325 74 3700

Request for Information Reference: 07.24.25

FOI Direct line: 01325 743700  
Email: [cdda-tr.cddftfoi@nhs.net](mailto:cdda-tr.cddftfoi@nhs.net)

Email only

10<sup>th</sup> July 2024

Dear

### **Freedom of Information Act 2000 – Request for Information**

Thank you for submitting a request for information which we received on 8<sup>th</sup> June 2024 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Diagnosed with Diffuse Large B Cell Lymphoma and I am providing the following information in response to your specific questions:

**1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

6

**a) Of these patients, how many commenced treatment at your trust within the last 6 months?**

6

**2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
  - R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
  - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
  - Axicabtagene ciloleucel
  - Tisagenlecleucel
  - Epcoritamab
  - Loncastuximab tesirine
  - Glofitamab
  - Any other SACT
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
- Axicabtagene ciloleucel (Yescarta)
  - Tisagenlecleucel
  - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  - Any other treatments

The Trust does not provide this service. The therapies are provided by South Tees and recorded on their database and the Trust presently does not have access to the data requested. If you wish to contact South Tees NHS Foundation Trust in accordance with Section 16 of the Act (duty to provide advice and assistance) you can do so via the following address:

South Tees NHS Foundation Trust  
Murray Building  
The James Cook University Hospital  
Marton Road  
Middlesbrough, TS4 3BW  
Email: [stees.foi.admin@nhs.net](mailto:stees.foi.admin@nhs.net)

4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  - Any other treatment

The Trust does not hold this information

**5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?**

There are no active clinical trials for DLBCL at the current time.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via [cdda-tr.cddffoi@nhs](mailto:cdda-tr.cddffoi@nhs).

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; [www.ico.gov.uk](http://www.ico.gov.uk).

Yours sincerely

**Corporate Records and Freedom of Information Facilitator**